Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 113Colorectal Neoplasms 73Stomach Neoplasms 48Pancreatic Neoplasms 45Rectal Neoplasms 40Neoplasms 29Neoplasm Metastasis 29Colonic Neoplasms 18Esophageal Neoplasms 16Triple Negative Breast Neoplasms 13Adenocarcinoma 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Gallbladder Neoplasms 9Bile Duct Neoplasms 8Brain Neoplasms 7Adenocarcinoma Of Esophagus 7Liver Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Cholangiocarcinoma 5Breast Neoplasms, Male 5Somatostatinoma 4Head and Neck Neoplasms 4Carcinoma, Hepatocellular 4Biliary Tract Neoplasms 4Gastrointestinal Neoplasms 3Gastrinoma 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Squamous Cell 3Carcinoma, Renal Cell 3Solid Tumor 2

Interventions

tucatinib 1sapanisertib 1Trastuzumab 1Rituximab 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Meningeal Neoplasms × Capecitabine × Clear all
NCT03501979 2025-08-29

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

University of Alabama at Birmingham

Phase 2 Terminated
17 enrolled 16 charts
Breast

Breast Neoplasms, Meningeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡